Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Actuarial Approach01:20

Actuarial Approach

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ascertainment of Cancer Cases in the German National Cohort (NAKO): Methods and Initial Results.

Deutsches Arzteblatt international·2026
Same author

Supplemental Breast Ultrasound in Mammography Screening for Women with Critically Dense Breasts.

Cancers·2026
Same author

Clinical characteristics and survival of small cell lung cancer with limited or extensive synchronous metastatic spread - A German population-based cancer-registry based cohort study.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Communication-related aspects drive senior patients' satisfaction with the process of decision-making in cancer therapy.

Scientific reports·2026
Same author

Social inequalities in cancer in Germany: a call to action.

Journal of cancer research and clinical oncology·2026
Same author

Nationwide analysis of acute promyelocytic leukemia: incidence and patient outcomes in Germany.

Haematologica·2026
Same journal

GLP-1 Receptor Agonists in Hidradenitis Suppurativa-Emerging Opportunities for Comorbidity Management?

JAMA dermatology·2026
Same journal

Topical Preparations for Moderate to Severe Rosacea Treatment: A Systematic Review and Network Meta-Analysis.

JAMA dermatology·2026
Same journal

GLP-1 Receptor Agonist Use and Clinical Outcomes in Patients With Hidradenitis Suppurativa.

JAMA dermatology·2026
Same journal

BRAF Inhibition in Congenital Nevi and Neural Melanosis.

JAMA dermatology·2026
Same journal

The Absent Original in Smartphone Photography.

JAMA dermatology·2026
Same journal

A Tribute to a Master Clinician: Richard Odom.

JAMA dermatology·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

Population Skin Cancer Screening and Melanoma Mortality Rates.

Joachim Hübner1, Laura Schumann2, Nora Eisemann2

  • 1Agency for Clinical Cancer Data of Lower Saxony, Oldenburg, Germany.

JAMA Dermatology
|June 10, 2026
PubMed
Summary
This summary is machine-generated.

Germany's national skin cancer screening (SCS) program, initiated in 2008, did not significantly reduce melanoma mortality rates compared to neighboring countries. Further investigation is needed to understand the program's limited effectiveness.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Related Experiment Videos

Last Updated: Jun 12, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Area of Science:

  • Public Health
  • Epidemiology
  • Dermatology

Background:

  • Germany implemented a nationwide population-based skin cancer screening (SCS) program in 2008.
  • The actual benefit of this intervention on melanoma mortality remains unclear.
  • Previous studies have also questioned the effectiveness of the German SCS program.

Purpose of the Study:

  • To evaluate the association between the German SCS program and melanoma mortality rates.
  • To compare melanoma mortality trends in Germany with neighboring countries lacking a similar population-based screening program.

Main Methods:

  • An ecological comparative effectiveness study design was employed.
  • Melanoma mortality data from 2009-2022 for 15 German federal states and 9 neighboring countries were analyzed.
  • Age-standardized melanoma mortality rates and annual percentage changes (APCs) were calculated using a random-effects model.

Main Results:

  • Melanoma mortality rates decreased in both Germany and control regions between 2009 and 2022.
  • Pooled APCs for melanoma mortality were -1.8% in Germany and -2.2% in control regions.
  • The difference in mortality trends between Germany and control regions was not statistically significant (P=.42).

Conclusions:

  • The German SCS program showed no statistically significant association with reduced melanoma mortality.
  • Findings align with prior research indicating a lack of demonstrable benefit.
  • Further research is recommended to identify reasons for the program's limited impact and inform future public health decisions.